Curcumin Down-Regulates DNA Methyltransferase 1 and Plays an Anti-Leukemic Role in Acute Myeloid Leukemia

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Yu, Jianhua ^a,b   Peng, Yong ^b   Wu, Lai Chu ^b,c   Xie, Zhiliang ^c   Deng, Youcai ^b,d   Hughes, Tiffany ^b   He, Shun ^b   Mo, XiaoKui ^c   Chiu, Ming ^c   Wang, Qi En ^b   He, Xiaoming ^b,e   Liu, Shujun ^f   Grever, Michael R ^a,b   Chan, Kenneth K ^b,c   Liu, Zhongfa ^b,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e Ohio State University   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE 1; PLACEBO; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; SYNAPTOTAGMIN I;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTILEUKEMIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; ENZYME REGULATION; EX VIVO STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DOWN-REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TUMOR CELLS, CULTURED;

EID: 84873935096     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055934     Document Type: Article

References (36)

1. Baylin SB, (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2Suppl 1: S4-11.
2. Jones PA, Baylin SB, (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
3. Issa JP, (2007) DNA methylation as a therapeutic target in cancer. Clin Cancer Res 13: 1634-1637.
4. Yoo CB, Jones PA, (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
5. Blum W, Marcucci G (2005) Targeting epigenetic changes in acute myeloid leukemia. Clin Adv Hematol Oncol 3: 855-865, 882.
6. Lyko F, Brown R, (2005) DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97: 1498-1506.
7. Lee BH, Yegnasubramanian S, Lin X, Nelson WG, (2005) Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 280: 40749-40756.
8. Siedlecki P, Garcia Boy R, Musch T, Brueckner B, Suhai S, et al. (2006) Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem 49: 678-683.
9. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F, (2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66: 2794-2800.
10. Shishodia S, Singh T, Chaturvedi MM, (2007) Modulation of transcription factors by curcumin. Adv Exp Med Biol 595: 127-148.
11. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC, (2006) Multiple biological activities of curcumin: a short review. Life Sci 78: 2081-2087.
12. Singh S, Khar A, (2006) Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 6: 259-270.
13. Menon VP, Sudheer AR, (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595: 105-125.
14. Shishodia S, Chaturvedi MM, Aggarwal BB, (2007) Role of curcumin in cancer therapy. Curr Probl Cancer 31: 243-305.
15. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, et al. (2004) Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279: 51163-51171.
16. Iersel ML, Ploemen JP, Struik I, van Amersfoort C, Keyzer AE, et al. (1996) Inhibition of glutathione S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem Biol Interact 102: 117-132.
17. Li XG, Chen Y, Wu Q, Liu HL, (2005) Effects of curcumin on the acetylation of histone H3, P53 and the proliferation of NB4 cells. Zhonghua Xue Ye Xue Za Zhi 26: 551-553.
18. Moiseeva EP, Almeida GM, Jones GD, Manson MM, (2007) Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther 6: 3071-3079.
19. Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, et al. (2009) Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett 19: 706-709.
20. Melisi D, Chiao PJ, (2007) NF-kappa B as a target for cancer therapy. Expert Opin Ther Targets 11: 133-144.
21. Liu S, Liu Z, Xie Z, Pang J, Yu J, et al. (2008) Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 111: 2364-2373.
22. Liu Z, Liu S, Xie Z, Blum W, Perrotti D, et al. (2007) Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Res 35: e31.
23. Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB, (2011) Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr 6: 93-108.
24. Christiansen DH, Andersen MK, Pedersen-Bjergaard J, (2003) Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17: 1813-1819.
25. Grovdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, et al. (2007) Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 13: 7107-7112.
26. Chim CS, Kwong YL, (2006) Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia. Leuk Lymphoma 47: 815-825.
27. Liu Z, Wu J, Xie Z, Liu S, Fan-Havard P, et al. (2009) Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry. Anal Biochem.
28. Plass C, Oakes C, Blum W, Marcucci G, (2008) Epigenetics in acute myeloid leukemia. Semin Oncol 35: 378-387.
29. de Vos D, van Overveld W, (2005) Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 84Suppl 1: 3-8.
30. Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, et al. (2007) Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 67: 6400-6408.
31. Fu S, Kurzrock R, (2010) Development of curcumin as an epigenetic agent. Cancer 116: 4670-4676.
32. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, et al. (2008) The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 118: 868-878.
33. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15524-15529.
34. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, et al. (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499.
35. Pouton CW, (2000) Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci 11Suppl 2: S93-98.
36. Zhongfa L, Chiu M, Wang J, Chen W, Yen W, et al. (2012) Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol 69: 679-689.